Amoxicillin and clavulanate potassium tablets are indicated for the treatment of lower respiratory tract infection due to confirmed or suspected beta-lactamase producing Haemophilus influenzae and Moraxella catarrhalis as follows [see Clinical Pharmacology (12.4) , Clinical Studies (14.1) ] : Amoxicillin and Clavulanate Potassium Tablets: adults and pediatric patients weighing greater than or equal to 40 kg Amoxic...
The recommended dosage and administration for the amoxicillin and clavulanate potassium tablets, depends on the indication, patient age, weight, and ability to swallow tablets. Therefore, carefully follow the recommended dosage and administration instructions specified below [see Dosage and Administration (2.2 , 2.4 , 2.6 and 2.8) ]. Amoxicillin and clavulanate potassium tablets should only be used in adults and p...
How Supplied Amoxicillin and Clavulanate Potassium Tablets USP, 875 mg/125 mg are white to off-white, capsule shaped, film-coated tablets, debossed with ‘X’ on one side and score line in between 3 and 2 on the other side, contains 875 mg of amoxicillin USP as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium). Bottles of 14 NDC 72789-456-14 Dispense i...
www.fda.gov/medwatchwww.fda.gov/STICAmoxicillin and clavulanate potassium tablets are indicated for the treatment of lower respiratory tract infection due to confirmed or suspected beta-lactamase producing Haemophilus influenzaeand Moraxella catarrhalisas follows [see Clinical Pharmacology (12.4), Clinical Studies (14.1)] :
Amoxicillin and clavulanate potassium tablets are indicated for the treatment of acute bacterial sinusitis due to confirmed or suspected beta-lactamase-producing Haemophilus influenzaeand Moraxella catarrhalisas follows [see Clinical Pharmacology (12.4), Clinical Studies (14.4)]:
Amoxicillin and clavulanate potassium tablets are indicated for the treatment of acute bacterial otitis media due to confirmed or suspected beta-lactamase-producing Haemophilus influenzaeand Moraxella catarrhalisas follows [see Use in Specific Populations (8.4), Clinical Studies (14.5)] :
Amoxicillin and clavulanate potassium tablets are indicated for the treatment of skin and skin structure infections due to confirmed or suspected beta-lactamase-producing S. aureus, Escherichia coli, and Klebsiellaspecies as follows [see Use in Specific Populations (8.4)] :
Amoxicillin and clavulanate potassium tablets are indicated for the treatment of urinary tract infections due to confirmed or suspected beta-lactamase-producing E. coli, Klebsiellaspecies, and Enterobacterspecies as follows [see Use in Specific Populations (8.4), Clinical Studies (14.2)]:
To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
The recommended dosage for adults and pediatric patients weighing 40 kg or more who are able to swallow tablets are provided in Table 1.
Amoxicillin and Clavulanate Potassium Tablets
Amoxicillin and clavulanate potassium tablets may be taken without regard to meals; however, absorption of clavulanate is enhanced when amoxicillin and clavulanate potassium tablets are administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, amoxicillin and clavulanate potassium tablets should be taken at the start of a meal.
Table 1. Recommended Dosage for Amoxicillin and Clavulanate Potassium Tablets in Adult and Pediatric Patients Weighing 40 kg or More
| Infection Type | Frequency | Dose | Formulation Strength |
| Amoxicillin and Clavulanate Potassium Tablets | |||
| Mild to Moderate Infections
| Every 12 hours
| One tablet
| 500 mg/125 mg
|
| Every 8 hours
| One tablet
| 250 mg/125 mg
| |
| Severe Infections
| Every 12 hours
| One tablet
| 875 mg/125 mg
|
| Every 8 hours
| One tablet
| 500 mg/125 mg
| |
For patients who are unable to swallow tablets, see Table 6 for guidance on substitution across formulations [see Dosage and Administration (2.8)].
AUGMENTIN ES-600 for Oral Suspension is not a substitute for Amoxicillin and Clavulanate Potassium Tablets in adults.
Amoxicillin and Clavulanate Potassium Tablets should not be used in pediatric patients weighing less than 40 kg due to different amoxicillin-to-clavulanic acid ratios [see Indications and Usage (1), Dosage and Administration (2.8), Use in Specific Populations (8.4)] .
Pediatric Patients Weighing 40 kg or More: Pediatric patients weighing 40 kg or more should receive the adult dose [see Indications and Usage (1), Dosage and Administration (2.2), Use in Specific Populations (8.4)] .
Amoxicillin and Clavulanate Potassium Tablets
A reduced dosage is recommended in patients with severe renal impairment (see Table 4). No dosage adjustment is recommended in patients with mild to moderate renal impairment.
Table 4: Recommended Dosage ofAmoxicillin and Clavulanate Potassium Tablets in Patients with Severe Renal Impairment
| Patients with Severe Renal Impairment | Dosage |
| GFR 10 mL/min to less than 30 mL/min
| 500 mg or 250 mg every 12 hours, depending on the severity of the infection
|
| GFR less than 10 mL/min
| 500 mg or 250 mg every 24 hours, depending on severity of the infection
|
| Hemodialysis
| 500 mg or 250 mg every 24 hours, depending on severity of the infection
Administer an additional dose both during and at the end of dialysis |
Patients with a GFR of less than 30 mL/min should not receive the 875 mg/125 mg dose of amoxicillin and clavulanate potassium tablets
Amoxicillin and Clavulanate Potassium Tablets
Table 6 provides guidance on selecting the appropriate strength when switching between Amoxicillin and Clavulanate Potassium Tablets and AUGMENTIN for Oral Suspension or Chewable Tablets to ensure the appropriate amoxicillin-to-clavulanic acid ratio.
Table 6: Selecting Appropriate Strengths ofAmoxicillin and Clavulanate PotassiumWhen Switching Between Tablets, Oral Suspension, or Chewable Tablets
| Amoxicillin and Clavulanate Potassium Tablet Strength | Substitutable Strength ofAUGMENTINfor Oral Suspension or Chewable Tabletsa |
| 250 mg/125 mg
b
| No equivalent available
|
| 500 mg/125 mg
c
| 125 mg/31.25 mg
or 250 mg/62.5 mg |
| 875 mg/125 mg
| 200 mg/28.5 mg
or 400 mg/57 mg |
| 1,000 mg/62.5 mg
| Not substitutable with immediate-release formulations
|
aOne Chewable Tablet has the same amount of amoxicillin and clavulanic acid as 5 mL of the corresponding strength of Oral Suspension. Chewable tablets may only be used as a substitute in pediatric patients weighing less than 40 kg.
bAmoxicillin and Clavulanate Potassium 250 mg/125 mg tablet is NOT substitutable with AUGMENTIN 250 mg/62.5 mg chewable tablet.
cTwo Amoxicillin and Clavulanate Potassium 250 mg/125 mg Tablets are not substitutable with one Amoxicillin and Clavulanate Potassium 500 mg/125 mg Tablet.
Amoxicillin and clavulanate potassium tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).
Amoxicillin and clavulanate potassium tablets are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with treatment with amoxicillin/clavulanate potassium.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with amoxicillin and clavulanate potassium, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. Amoxicillin and clavulanate potassium is contraindicated in patients with a history of serious hypersensitivity reactions to amoxicillin, clavulanate, or to other beta-lactam antibacterial drugs [see Contraindications (4.1)] . If an allergic reaction occurs, discontinue amoxicillin and clavulanate potassium and institute appropriate therapy.
Amoxicillin and clavulanate potassium may cause severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash, they should be monitored closely, and amoxicillin and clavulanate potassium discontinued if lesions progress.
Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of amoxicillin and clavulanate potassium tablets [see Adverse Reactions (6.2)] , with most cases occurring in pediatric patients. DIES is a non-IgE mediated hypersensitivity reaction characterized by protracted vomiting occurring 1 to 4 hours after drug ingestion in the absence of skin or respiratory symptoms. DIES may be associated with pallor, lethargy, hypotension, shock, diarrhea within 24 hours after ingesting amoxicillin, and leukocytosis with neutrophilia. If DIES occurs, discontinue amoxicillin and clavulanate potassium and institute appropriate therapy.
Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of amoxicillin and clavulanate potassium. Hepatotoxicity is usually reversible; however, deaths have been reported. These cases have generally been associated with serious underlying diseases or concomitant medications. Amoxicillin and clavulanate potassium is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with treatment with amoxicillin and clavulanate potassium [see Contraindications (4.2), Use in Specific Populations (8.7), Adverse Reactions (6.2)] .
Clostridioidesdifficile
-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin and clavulanate potassium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
C. difficile.
C. difficileproduces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of
C. difficilecause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against
C. difficilemay need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of
C. difficile, and surgical evaluation should be instituted as clinically indicated.
A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Avoid amoxicillin and clavulanate potassium use in patients with mononucleosis [see Adverse Reactions (6.2)] .
The possibility of superinfections with mycotic or bacterial pathogens should be considered during therapy. If superinfections occur (commonly involving Pseudomonasspp. or Candidaspp.), discontinue amoxicillin and clavulanate potassium and institute appropriate therapy.
Prescribing amoxicillin and clavulanate potassium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Amoxicillin and Clavulanate Potassium Tablets
The most frequently reported adverse reactions in clinical trials were diarrhea/loose stools (9%), nausea (3%), skin rash and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy due to adverse reactions. The overall incidence of adverse reactions, particularly diarrhea, increased with higher recommended doses. Other less frequently reported adverse reactions (<1%) included abdominal discomfort, flatulence, and headache.
In two pivotal trials in adults with lower respiratory tract or urinary tract infections ,the overall incidence of adverse reactions was similar between amoxicillin and clavulanate potassium 875 mg/125 mg tablets every 12 hours and amoxicillin and clavulanate potassium 500 mg/125 mg tablets every 8 hours [see Clinical Studies (14.1, 14.2)]. The most common adverse reaction was diarrhea, reported in 15% of patients receiving amoxicillin and clavulanate potassium tablets 875 mg/125 mg every 12 hours and 14% of patients receiving amoxicillin and clavulanate potassium tablets 500 mg/125 mg every 8 hours. The rate of severe diarrhea or discontinuation due to diarrhea was 1% versus 2%, respectively.
The following adverse reactions have been identified during postmarketing use of amoxicillin and clavulanate potassium products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal:Drug-induced enterocolitis syndrome (DIES), diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment
[see
Warnings and Precautions (5.3,
5.5)].
Immune:Hypersensitivity reactions, anaphylactic reactions (including shock), angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), hypersensitivity vasculitis
[see
Warnings and Precautions (5.1)].
Skin and Appendages:Rashes, pruritus, urticaria, erythema multiforme, SJS, TEN, DRESS, AGEP, exfoliative dermatitis, and linear IgA bullous dermatosis
[see
Warnings and Precautions (5.1,
5.2,
5.6)].
Liver:A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibacterials. Hepatic dysfunction, including increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with amoxicillin and clavulanate potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. Deaths have been reported
[see
Contraindications (4.2),
Warnings and Precautions (5.4)].
Renal:Interstitial nephritis and hematuria have been reported. Crystalluria has also been reported
[see
Overdosage (10)].
Hemic and Lymphatic Systems:Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. There have been reports of increased prothrombin time in patients receiving amoxicillin and clavulanate potassium and anticoagulant therapy concomitantly
[see
Drug Interactions (7.2)].
Central Nervous System: Agitation, anxiety, behavioral changes, aseptic meningitis, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported.
Miscellaneous:Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.
Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with amoxicillin and clavulanate potassium may result in increased and prolonged blood levels of amoxicillin. Co-administration of probenecid is not recommended.
Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.
The concurrent administration of allopurinol and amoxicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients. Discontinue allopurinol at the first appearance of skin rash when used concomitantly with amoxicillin and clavulanate potassium.
High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST ®, Benedict’s Solution, or Fehling’s Solution. Therefore, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
Risk Summary
Available data from published epidemiologic studies and pharmacovigilance case reports over several decades of use with amoxicillin and clavulanate during pregnancy have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes. A study in women with preterm prelabor rupture of membranes (PPROM) reported that prophylactic treatment with amoxicillin and clavulanate may be associated with an increased risk of necrotizing enterocolitis in neonates (see Data). Reproduction studies conducted in pregnant rats, given doses greater than or equal to 4 and 10 times the Maximum Recommended Human Dose (MRHD) of amoxicillin trihydrate and clavulanate respectively in amoxicillin and clavulanate potassium based on body surface area, revealed no evidence of fetal harm (see Data).
The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Human Data
One randomized, controlled trial included 4,826 pregnant women with premature rupture of fetal membranes who were randomly assigned to 250 mg erythromycin (n=1,197), 250 mg amoxicillin and 125 mg clavulanate (n=1,212), amoxicillin and clavulanate plus erythromycin (n=1,192), or placebo (n=1,225) four times daily for 10 days or until delivery. Amoxicillin and clavulanate was associated with a significantly increased rate of proven neonatal necrotizing enterocolitis: 1.9% (n=24) in the amoxicillin and clavulanate only group versus 0.5% (n=6) in the placebo group (p=0.001), and 1.8% (n=44) in the any amoxicillin and clavulanate group versus 0.7% (n=17) in the no amoxicillin and clavulanate group (p=0.0005).
Animal Data
In an embryofetal developmental study in pregnant rats, amoxicillin and clavulanate (2:1 ratio formulation of amoxicillin:clavulanate) were administered at oral doses up to 1,200 mg/kg/day during the period of organogenesis (gestation days (GD) 6 to 15). No evidence of fetal harm was observed. Based on body surface area comparisons, the dose corresponds to approximately 4 times the MRHD for amoxicillin trihydrate and 10 times the MRHD for clavulanate potassium.
In a pre-and postnatal developmental study in pregnant rats, amoxicillin and clavulanate (2:1 ratio formulation of amoxicillin:clavulanate) were administered at oral doses up to 1,200 mg/kg/day beginning from GD 15 through Day 21 of lactation. No effects on maternal reproductive function or on developmental and reproductive parameters of the offspring were observed up to the highest dose, corresponding to approximately 4 times the MRHD for amoxicillin trihydrate and 10 times the MRHD for clavulanate potassium, based on body surface area comparisons.
Risk Summary
Data from a published clinical lactation study report that amoxicillin is present in human milk. There are reports of diarrhea, irritability, and rash in infants exposed to amoxicillin and clavulanate through breast milk; therefore, infants exposed to amoxicillin and clavulanate potassium should be monitored for these symptoms. There are no data on the effects of amoxicillin and clavulanate on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for amoxicillin and clavulanate potassium and any potential adverse effects on the breastfed child from amoxicillin and clavulanate potassium or from the underlying maternal condition.
The five amoxicillin and clavulanate potassium dosage forms (tablets, chewable tablets, oral suspension, XR tablets, and ES-600 for oral suspension) are different products. They are approved for different pediatric indications, age groups, and weights; have different dosing regimens; and have different preparation and administration instructions. Therefore, select the recommended dosage form based on the pediatric indication, age group, and weight [see Dosage and Administration (2)].
Lower Respiratory Tract Infections
The safety and effectiveness of amoxicillin and clavulanate potassium have been established for the treatment of lower respiratory tract infections due to confirmed or suspected beta-lactamase producing isolates of
Haemophilus influenzaeand
Moraxella catarrhalisas follows
[see
Indications and Usage (1.1),
Clinical Pharmacology (12.3),
Clinical Studies (14.1)
]:
Data are insufficient to support extrapolation in these age groups due to developmental differences in renal function. Elimination of amoxicillin may be delayed, while clavulanate elimination is not altered. Dosage should be modified in pediatric patients less than 12 weeks (3 months) [see Dosage and Administration (2.3)] .
Of the 3,119 patients included in clinical studies of amoxicillin and clavulanate potassium tablets, 32% were 65 years of age and older and 14% were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other clinical experience has not identified differences in responses between elderly and younger patients.
Amoxicillin and clavulanate potassium is substantially excreted by the kidney, and the risk of adverse reactions to amoxicillin and clavulanate potassium may be greater in patients with renal impairment than in patients with normal renal function. Because geriatric patients are more likely to have renal impairment, monitor for adverse reactions. Dosage adjustment is recommended in patients with severe renal impairment [see Dosage and Administration (2.6), Use in Specific Populations (8.6)] .
Amoxicillin is primarily eliminated by the kidney. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis.
Amoxicillin and Clavulanate Potassium
No dosage adjustment is recommended in patients with mild to moderate renal impairment. A reduced dosage is recommended in patients with severe renal impairment (GFR less than 30 mL/min)
.Patients with a GFR of less than 30 mL/min should not receive the 875 mg/125 mg dose of amoxicillin and clavulanate potassium
[see
Dosage and Administration (2.6)]
.
Monitor hepatic function as appropriate during therapy with amoxicillin and clavulanate potassium [see Contraindications (4.2), Warnings and Precautions (5.4)] .
Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients.
In the case of overdosage, discontinue amoxicillin and clavulanate potassium, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.
1Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.
Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.
Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis.
Amoxicillin and clavulanate potassium tablets, USP are an oral antibacterial combination consisting of the semisynthetic antibacterial amoxicillin and the beta-lactamase inhibitor clavulanate potassium (the potassium salt of clavulanic acid).
Amoxicillin USP is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid.
Amoxicillin trihydrate has a molecular formula of C 16H 19N 3O 5S•3H 2O and a molecular weight of 419.46. Chemically, it is (2 S,5 R,6 R)-6-[( R)-(-)-2-Amino-2-( p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid trihydrate and may be represented structurally as:
Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a beta-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of beta-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins.
Clavulanate potassium has a molecular formula of C 8H 8KNO 5and a molecular weight of 237.25. Chemically, clavulanate potassium is potassium ( Z)-( 2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as:
Each amoxicillin and clavulanate potassium tablet contains 25 mg of potassium.
Inactive Ingredients:
Colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, surelease clear (aqueous ethyl cellulose dispersion), and titanium dioxide.
Amoxicillin and clavulanate potassium is an antibacterial drug [see Clinical Pharmacology (12.4)].
The antibacterial activity of amoxicillin/clavulanate is primarily driven by the percentage of the dosing interval during which unbound (free) amoxicillin plasma concentrations exceed the minimum inhibitory concentration (% fT>MIC) of the target bacterial organism. Clavulanate inhibits β-lactamase enzymes and thereby restores activity of amoxicillin against certain β-lactamase–producing bacteria.
Absorption
Amoxicillin and Clavulanate Potassium Tablets
Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While amoxicillin and clavulanate potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In one study, the relative bioavailability of clavulanate was reduced when amoxicillin and clavulanate potassium was dosed at 30 and 150 minutes after the start of a high‑fat breakfast.
Mean amoxicillin and clavulanate potassium pharmacokinetic parameters in healthy adult subjects following administration of amoxicillin and clavulanate potassium tablets are shown in Table 7.
Table 7: Mean (±S.D.) Amoxicillin and Clavulanate Potassium Pharmacokinetic Parameters a,b with Amoxicillin and Clavulanate PotassiumTablets
| Dosing Regimen | C
max(mcg/mL)
| AUC
0-24(mcg*h/mL)
| ||
| Amoxicillin
| Clavulanate potassium
| Amoxicillin
| Clavulanate potassium
| |
| 250 mg/125 mg every 8 hours
| 3.3 ± 1.12
| 1.5 ± 0.70
| 26.7 ± 4.56
| 12.6 ± 3.25
|
| 500 mg/125 mg every 12 hours
| 6.5 ± 1.41
| 1.8 ± 0.61
| 33.4 ± 6.76
| 8.6 ± 1.95
|
| 500 mg/125 mg every 8 hours
| 7.2 ± 2.26
| 2.4 ± 0.83
| 53.4 ± 8.87
| 15.7 ± 3.86
|
| 875 mg/125 mg every 12 hours
| 11.6 ± 2.78
| 2.2 ± 0.99
| 53.5 ± 12.31
| 10.2 ± 3.04
|
aMean (± standard deviation) values of 14 healthy adult subjects (n= 15 for clavulanate in the low-dose regimens). Peak concentrations occurred ~1.5 hours after the dose.
bAdministered at the start of a light meal.
Distribution
The protein binding of amoxicillin and clavulanic acid to human serum is approximately 18% and 25%, respectively. Amoxicillin diffuses readily into most body tissues and fluids, with the exception of the brain and spinal fluid.
Metabolism and Excretion
The half-life of amoxicillin after the oral administration of amoxicillin and clavulanate potassium is approximately 1.3 hours and that of clavulanic acid is approximately 1 hour.
Amoxicillin and Clavulanate Potassium Tablets
Following administration of a single 250 mg/125 mg or 500 mg/125 mg tablet, approximately 50 to 70% of amoxicillin and approximately 25 to 40% of clavulanic acid are excreted unchanged in urine during the first 6 hours.
Drug Interaction Studies
Clinical Studies
Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid [see Drug Interactions (7.1)] .
Mechanism of Action
Amoxicillin binds to penicillin-binding proteins within the bacterial cell wall and inhibits bacterial cell wall synthesis. Clavulanic acid is a beta-lactam, structurally related to penicillin, that may inactivate certain beta‑lactamase enzymes.
Resistance
Resistance to penicillins may be mediated by destruction of the beta-lactam ring by a beta-lactamase, altered affinity of penicillin for target, or decreased penetration of the antibacterial drug to reach the target site. Amoxicillin alone is susceptible to degradation by beta‑lactamases, and therefore its spectrum of activity does not include bacteria that produce these enzymes.
Antimicrobial Activity
Amoxicillin and clavulanic acid has been shown to be active against most isolates of the following microorganisms, both
in vitroand in clinical infections
[see
Indications and Usage (1)]
.
Lower Respiratory Tract Infections
Gram-negative bacteria:
Haemophilus influenzae
Moraxella catarrhalis
Acute Bacterial Sinusitis
Gram-positive bacteria:
Staphylococcus aureus(methicillin-susceptible)
Streptococcus pneumoniae
Gram-negative bacteria:
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella pneumoniae
Moraxella catarrhalis
Acute Bacterial Otitis Media
Gram-positive bacteria:
Streptococcus pneumoniae
Gram-negative bacteria:
Haemophilus influenzae
Moraxella catarrhalis
Skin and Skin Structure Infections
Gram-positive bacteria:
Staphylococcus aureus(methicillin-susceptible)
Gram-negative bacteria:
Escherichia coli
Klebsiella spp.
Urinary Tract Infections
Gram-negative bacteria (including beta-lactamase-producing strains):
Escherichia coli
Klebsiellaspp.
Enterobacter spp.
The following in vitrodata are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit in vitrominimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for amoxicillin and clavulanic acid against isolates of similar genus or organism group. However, the efficacy of amoxicillin and clavulanic acid in treating clinical infections caused by these bacteria have not been established in adequate and well-controlled trials.
Gram-positive bacteria:
Enterococcus faecalis
Staphylococcus epidermidis
Staphylococcus saprophyticus
Streptococcus pyogenes
Viridans group Streptococcus
Gram-negative Bacteria
Eikenella corrodens
Proteus mirabilis
Anaerobic Bacteria
Bacteroides species including Bacteroides fragilis
Fusobacterium species
Peptostreptococcus species
Susceptibility Testing:
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see www.fda.gov/STIC.
Carcinogenesis
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Mutagenesis
Amoxicillin and clavulanate (4:1 ratio formulation of amoxicillin:clavulanate) was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Amoxicillin and clavulanate was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at concentrations that were also associated with decreased cell survival. Amoxicillin and clavulanate was negative in the mouse micronucleus test, and in the dominant lethal assay in mice. Clavulanate potassium alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test and was negative in each of these assays.
Impairment of Fertility
Amoxicillin and clavulanate (2:1 ratio formulation of amoxicillin:clavulanate) at oral doses of up to 1,200 mg/kg/day was found to have no effect on fertility and reproductive performance in rats. Based on body surface area comparisons, these doses correspond to approximately 4 times the MRHD for adults for amoxicillin trihydrate and 10 times the MRHD for clavulanate potassium.
A randomized, controlled trial was conducted in 562 adults with lower respiratory tract infections, comparing amoxicillin and clavulanate potassium tablets 875 mg/125 mg every 12 hours with amoxicillin and clavulanate potassium tablets 500 mg/125 mg every 8 hours. Comparable efficacy was demonstrated between the two regimens.
A randomized, controlled trial was conducted in adults with pyelonephritis (n=361) or complicated urinary tract infection (n=268), defined as urinary tract abnormalities that predispose to relapse after bacteriuria eradication. Patients were randomized 1:1 to receive amoxicillin and clavulanate potassium tablets 875 mg/125 mg every 12 hours (n=308) or amoxicillin and clavulanate potassium tablets 500 mg/125 mg every 8 hours (n=321). Among bacteriologically evaluable patients, bacteriologic success rates were comparable between the two dosing regimens when assessed immediately after therapy and at follow-up visits.
Table 13: Bacteriologic Efficacy Rates in Complicated Urinary Tract Infections in Adults
| Time Post Therapy | 875 mg every 12 hours % (n) | 500 mg every 8 hours % (n) |
| 2 to 4 days
| 81% (58)
| 80% (54)
|
| 5 to 9 days
| 58% (41)
| 52% (52)
|
| 2 to 4 weeks
| 52% (101)
| 55% (104)
|
Adults with a diagnosis of acute bacterial sinusitis (ABS) were evaluated in 3 clinical studies. In one study, 363 patients were randomized to receive either AUGMENTIN XR Extended-Release Tablets 2,000 mg/125 mg orally every 12 hours or levofloxacin 500 mg orally daily for 10 days in a double‑blind, multicenter, prospective trial. These patients were clinically and radiologically evaluated at the test of cure (day 17 to 28) visit. The combined clinical and radiological responses were 84% for AUGMENTIN XR Extended-Release Tablets and 84% for levofloxacin at the test of cure visit in clinically evaluable patients (95% CI for the treatment difference equals ‑9.4, 8.3). The clinical response rates at the test of cure were 87% and 89%, respectively.
The other 2 trials were non‑comparative, multicenter studies designed to assess the bacteriological and clinical efficacy of AUGMENTIN XR Extended-Release Tablets (2,000 mg/125 mg orally every 12 hours for 10 days) in the treatment of 2,288 patients with ABS. Evaluation timepoints were the same as in the prior study. Patients underwent maxillary sinus puncture for culture prior to receiving study medication. Patients with acute bacterial sinusitis due to S. pneumoniaewith reduced susceptibility to penicillin were accrued through enrollment in these 2 open‑label non‑comparative clinical trials. Clinical success rates for key pathogens in these studies are shown in Table 15.
Table 15: Clinical Success Rates in Patients with Acute Bacterial Sinusitis
| Penicillin MICs of
S. pneumoniaeIsolates
| Intent-To-Treat | Clinically Evaluable | ||||
| n/N
a
| % | 95% CI
b
| n/N
a
| % | 95% CI
b
| |
| All
S. pneumoniae
| 344/370
| 93
| -
| 318/326
| 98
| -
|
| MIC greater than or equal to2.0 mcg/mL
c
| 35/36
| 97
| 85.5, 99.9
| 30/31
| 96
| 83.3, 99.9
|
| MIC equal to 2.0 mcg/mL
| 23/24
| 96
| 78.9, 99.9
| 19/20
| 95
| 75.1, 99.9
|
| MIC greater than or equal to4.0 mcg/mL
d
| 12/12
| 100
| 73.5, 100
| 11/11
| 100
| 71.5, 100
|
| H. influenzae | 265/305
| 87
| -
| 242/259
| 93
| -
|
| M. catarrhalis | 94/105
| 90
| -
| 86/90
| 96
| -
|
an/N equals patients with pathogen eradicated or presumed eradicated/total number of patients.
bConfidence limits calculated using exact probabilities.
cS. pneumoniaestrains with penicillin MICs of greater than or equal to 2 mcg/mL are considered resistant to penicillin.
dIncludes one patient each with S. pneumoniaepenicillin MICs of 8 and 16 mcg/mL.
One randomized, controlled US/Canadian clinical trial evaluated two dosing regimens for AUGMENTIN for Oral Suspension in pediatric patients (aged 2 months to 12 years) with acute otitis media. Patients received either 45 mg/6.4 mg/kg/day divided every 12 hours or 40 mg/10 mg/kg/day divided every 8 hours for 10 days. A total of 575 patients were enrolled, with ≥84% evaluable in each group.
Clinical cure rates obtained in the evaluable patients at the end of therapy and follow-up visits are presented in Table 16.
Table 16: Clinical Cure Rates at End of Therapy and Follow-Up Visits
| AUGMENTIN 45 mg/kg/day, divided every 12 hours | AUGMENTIN 40 mg/kg/day, divided every 8 hours | |
| Clinical Cure at End of Therapy Visit
a
| 87%
(n=265) | 82%
(n=260) |
| Clinical Cure at Follow-Up Visit
| 67%
(n= 249) | 69%
(n=243) |
aClinical cure at end of therapy visit was defined as 2 to 4 days after the completion of therapy.
bClinical cure at follow-up visit was defined as 22 to 28 days post‑completion of therapy.
1. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67.
How Supplied
Amoxicillin and Clavulanate Potassium Tablets USP, 875 mg/125 mgare white to off-white, capsule shaped, film-coated tablets, debossed with ‘X’ on one side and score line in between 3 and 2 on the other side, contains 875 mg of amoxicillin USP as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).
Bottles of 14 NDC 72789-456-14
Dispense in a tight container [see USP]. Advise patients to keep in a closed container. Use only if inner seal is intact.
Storage
Store amoxicillin and clavulanate potassium tablets, USP at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Keep out of the reach of children.
Allergic Reactions
Counsel patients that amoxicillin and clavulanate potassium tablets contains a penicillin class drug product that can cause allergic reactions in some individuals [see Warnings and Precautions (5.1, 5.3)].
Severe Cutaneous Adverse Reactions (SCAR)
Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking amoxicillin and clavulanate potassium tablets immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity [see Warnings and Precautions (5.2)] .
Diarrhea
Counsel patients that diarrhea is a common problem caused by antibacterial drugs, including Amoxicillin and clavulanate potassium tablets, which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible. If diarrhea develops and is severe or lasts more than 2 or 3 days, advise the patients to call their doctor
[see
Warnings and Precautions (5.5)]
.
Antibacterial Resistance
Patients should be counseled that antibacterial drugs, including amoxicillin and clavulanate potassium tablets, should only be used to treat bacterial infections. Antibacterial drugs do not treat viral infections (e.g., the common cold). When amoxicillin and clavulanate potassium tablet is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin and clavulanate potassium tablets or other antibacterial drugs in the future
[see
Warnings and Precautions (5.9)]
.
The brands listed are the trademarks of their respective owners and are not trademarks of the Aurobindo Pharma Limited.
Distributed by:
Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520
Manufactured by:
Aurobindo Pharma Limited
Hyderabad-500 032, India
Revised: 09/2026
Rx only
Amoxicillin and
Clavulanate Potassium
Tablets, USP
875 mg/125 mg*
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | Data Matrix | (01)00372789456140(21)L24B63000007(17)260731(10)L24B63 | GTIN-14: 00372789456140 GTIN-12: 372789456140 UPC-A: 372789456140 EAN-13: 0372789456140 GTIN storage (14 digits): 00372789456140 | 72789456.jpg |
| Barcode | EAN-13 | 0372789456140 | GTIN-13: 0372789456140 EAN-13: 0372789456140 GTIN-12: 372789456140 UPC-A: 372789456140 GTIN storage (14 digits): 00372789456140 | 72789456.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 502415e5-4ac7-4266-a01a-ef44aa3c028d | Product name | 7 | 20250623 |
| d0f377c9-74d8-e2e3-e06e-4d37534f5c0f | Product name | 3 | 20250620 |
| 2ebbc361-d28f-48a9-a286-c1ae09cdaf5c | Product name | 3 | 20230314 |
| 2bb254ff-3d7f-4bdb-abf9-476506008c55 | Product name | 1 | 20230117 |
| f33561b9-47cb-411c-a228-16c62e346cd4 | Product name | 1 | 20200415 |
| 8690a824-4bf8-4d1e-b118-2d6dda86bc04 | Product name | 2 | 20161206 |
| cf3f1c02-1f32-2322-3314-b70ebbf5610e | Product name | 1 | 20140508 |
| ebb3e917-326a-9e18-0354-a19c9f63a2f3 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 72789-456-14 | EA - Each | 72789-456 | 7d683e8d-00d3-4c27-939c-7360ec980439 | 1 | 2025-02-10 |
| 65862-503-01 | EA - Each | 65862-503 | e9f771e4-123e-4f4b-9bc9-78bb525faaab | 1 | 2012-07-24 |
| 65862-503-20 | EA - Each | 65862-503 | 9179cba0-9e32-4072-8ce8-e25ae66ba740 | 1 | 2012-07-24 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 72789-456 | 72789-456-14 |
| 65862-503 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 24 | 2026-03-20 | full-release | 2026-05-31 22:10:46 |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | AMOXICILLIN; CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 |
| Application-product | TE code |
|---|---|
| A091568-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A091568-001 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | TABLET / ORAL | AB | 2012-01-20 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091568-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A091568-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A091568-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091568-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A091568-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091568-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091568-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091568-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091568-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091568-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091568-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A091568-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091568-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091568-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091568-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A091568-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091568-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A091568-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A091568-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A091568-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A091568-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A091568-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091568-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A091568-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A091568-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A091568-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A091568-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A091568-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A091568-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A091568-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A091568-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A091568-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A091568-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A091568-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A091568-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A091568-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A091568-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A091568-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A091568-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A091568-001 | AB | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4d7ba437-b03d-da23-e063-6394a90ac533 | 7ef8592d-c7d0-49a4-a559-3190e559fa2f | 2026-03-20 | Warnings, Adverse reactions | 7ef8592d-c7d0-49a4-a559-3190e559fa2f |
Adverse event summaries are temporarily unavailable. Other product information remains available.